International Journal of Clinical Pediatric Dentistry

Register      Login

VOLUME 17 , ISSUE 1 ( January, 2024 ) > List of Articles

CASE REPORT

Angiogenesis Inhibitor Drug-induced Benign Migratory Glossitis in a Patient of Juvenile-onset Recurrent Respiratory Papillomatosis under Maintenance Therapy

Namita Kalra, Rishi Tyagi, Amit Khatri, Khadeeja Kulood, Puja Sabherwal

Keywords : Angiogenesis inhibitor, Benign migratory glossitis, Case report, Juvenile-onset recurrent respiratory papillomatosis, Oral mucosal

Citation Information : Kalra N, Tyagi R, Khatri A, Kulood K, Sabherwal P. Angiogenesis Inhibitor Drug-induced Benign Migratory Glossitis in a Patient of Juvenile-onset Recurrent Respiratory Papillomatosis under Maintenance Therapy. Int J Clin Pediatr Dent 2024; 17 (1):92-96.

DOI: 10.5005/jp-journals-10005-2739

License: CC BY-NC 4.0

Published Online: 14-03-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Background: Benign migratory glossitis or geographic tongue is a chronic recurring inflammatory condition of the oral cavity. With its ephemeral characteristics, there has been reported literature showing its association with the administration of certain drugs including angiogenesis inhibitors. The antiangiogenic drugs act by selectively inhibiting the vascular endothelial growth factor (VEGF) signaling. It has been widely used as an adjunct and a maintenance agent for the treatment of various cancers. Aims: This study aims to report probable characteristic oral mucosal changes in a patient with juvenile-onset recurrent respiratory papillomatosis (JORRP) under maintenance therapy with an antiangiogenesis drug. Case description: The patient was presented with a burning sensation on having spicy food. This occurred after the completion of three cycles of bevacizumab infusion. It was associated with the appearance of migratory lesions over the tongue and evolved periods of remission and exacerbation. Clinical examination revealed lesions characteristic of the geographic tongue on the anterior two-thirds of the dorsal surface as well as the lateral surface of the tongue classified as type 2, according to Hume criteria. Oral examination revealed dental caries in relation to 52, 54, 62, 63, 74, and 85 teeth and grossly decayed 64. Topical lignocaine gel was instituted for symptomatic relief of the lesion. Full mouth rehabilitation with preventive and restorative therapeutic interventions was carried out. Clinical significance and conclusion: The documented literature along with this report put forth a probable association of geographic tongue with the use of bevacizumab drugs which requires further detailed studies. These lesions generally require symptomatic treatment with assurance only. The etiology is poorly understood.


PDF Share
  1. Campana F, Vigarios E, Fricain JC, et al. Geographic stomatitis with palate involvement. An Bras Dermatol 2019;94(4):449–451. DOI: 10.1590/abd1806-4841.20197774
  2. Nandini DB, Bhavana SB, Deepak BS, et al. Paediatric geographic tongue: a case report, review and recent updates. J Clin Diagn Res. 2016;10(2):ZE05–ZE09. DOI: 10.7860/JCDR/2016/16452.7191
  3. Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncologist 2010;15(8):819–825. DOI: 10.1634/theoncologist.2009-0317
  4. Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev 2020;86:102017. DOI: 10.1016/j.ctrv.2020.102017
  5. Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 2015;93:52–79. DOI: 10.1016/j.ejpb.2015.03.018
  6. Lam SY, Lee CS, Sharma S, et al. Bevacizumab-induced dysphonia: a case report with brief review of literature. J Oncol Pharm Pract 2020;26(4):1032–1036. DOI: 10.1177/1078155219889388
  7. Gavrilovic IT, Balagula Y, Rosen AC, et al. Characteristics of oral mucosal events related to bevacizumab treatment. Oncologist 2012;17(2):274–278. DOI: 10.1634/theoncologist.2011-0198
  8. Di Lorenzo G, Porta C, Bellmunt J, et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 2011;59(4):526–540. DOI: 10.1016/j.eururo.2011.01.002
  9. Martinez-Garcia M, Roman-Sainz J, Silvestre-Torner N, et al. Bevacizumab-induced geographic tongue. Dermatol Pract Concept 2021;11(3):e2021043. DOI: 10.5826/dpc.1103a43
  10. Sundar S, Burge F. Geographical tongue induced by axitinib. BMJ Case Rep 2015;2015:bcr2015211318. DOI: 10.1136/bcr-2015-211318
  11. Ryan MA, Leu GR, Upchurch PA, et al. Systemic Bevacizumab (Avastin) for juvenile-onset recurrent respiratory papillomatosis: a systematic review. Laryngoscope 2021;131(5):1138–1146. DOI: 10.1002/lary.29084
  12. Strong MS, Vaughan CW, Cooperband SR, et al. Recurrent respiratory papillomatosis: management with the CO2 laser. Ann Otol Rhinol Laryngol 1976;85(4 Pt 1):508–516. DOI: 10.1177/000348947608500412
  13. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239–245. DOI: 10.1038/clpt.1981.154
  14. Hume WJ. Geographic stomatitis: a critical review. J Dent 1975;3(1):25–43. DOI: 10.1016/0300-5712(75)90020-2
  15. Shibuya M. Vascular Endothelial Growth Factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2011;2(12):1097–1105. DOI: 10.1177/1947601911423031
  16. Niu G, Chen X. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets 2010;11(8):1000–1017. DOI: 10.2174/138945010791591395
  17. Johnson KE, Wilgus TA. Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair. Adv Wound Care (New Rochelle) 2014;3(10):647–661. DOI: 10.1089/wound.2013.0517
  18. Pammer J, Weninger W, Mildner M, et al. Vascular endothelial growth factor is constitutively expressed in normal human salivary glands and is secreted in the saliva of healthy individuals. J Pathol 1998;186(2):186–191. DOI: 10.1002/(SICI)1096-9896(1998100)186:2<186::AID-PATH148>3.0.CO;2-J
  19. Cutright DE, Bauer H. Cell renewal in the oral mucosa and skin of the rat. I. Turnover time. Oral Surg Oral Med Oral Pathol 1967;23(2):249–259. DOI: 10.1016/0030-4220(67)90104-1
  20. Wolff A, Joshi RK, Ekström J, et al. A guide to medications inducing salivary gland dysfunction, xerostomia, and subjective sialorrhea: a systematic review sponsored by the world workshop on oral medicine VI. Drugs R D 2017;17(1):1–28. DOI: 10.1007/s40268-016-0153-9
  21. Hubiche T, Valenza B, Chevreau C, et al. Geographic tongue induced by angiogenesis inhibitors. Oncologist 2013;18(4):e16–e17. DOI: 10.1634/theoncologist.2012-0320
  22. Fang P, Hu JH, Cheng ZG, et al. Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials. PLoS One 2012;7(12):e49717. DOI: 10.1371/journal.pone.0049717
  23. Maluf G, Caldas RJ, Fregnani ER, et al. A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants. Int J Implant Dent 2019;5(1):34. DOI: 10.1186/s40729-019-0188-0
  24. Santos-Silva AR, Belizário Rosa GA, Castro Júnior Gd, et al. Osteonecrosis of the mandible associated with bevacizumab therapy. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;115(6):e32–e36. DOI: 10.1016/j.oooo.2013.02.001
  25. Takahashi H, Sato M, Tsukada K, et al. A retrospective study of oral adverse events with colorectal cancer chemotherapy using bevacizumab. Gan To Kagaku Ryoho 2011;38(6):959–962.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.